0001209191-21-059131.txt : 20211004
0001209191-21-059131.hdr.sgml : 20211004
20211004181127
ACCESSION NUMBER: 0001209191-21-059131
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210929
FILED AS OF DATE: 20211004
DATE AS OF CHANGE: 20211004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vieser Jaime
CENTRAL INDEX KEY: 0001846045
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33038
FILM NUMBER: 211304376
MAIL ADDRESS:
STREET 1: ONE FIRST AVENUE, PARRIS BUILDING 34
STREET 2: NAVY YARD PLAZA
CITY: BOSTON
STATE: MA
ZIP: 02129
FORMER NAME:
FORMER CONFORMED NAME: Vieser Jamie
DATE OF NAME CHANGE: 20210212
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ZIOPHARM ONCOLOGY INC
CENTRAL INDEX KEY: 0001107421
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 841475642
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE FIRST AVENUE
STREET 2: PARRIS BUILDING 34, NAVY YARD PLAZA
CITY: BOSTON
STATE: MA
ZIP: 02129
BUSINESS PHONE: 617-259-1970
MAIL ADDRESS:
STREET 1: ONE FIRST AVENUE
STREET 2: PARRIS BUILDING 34, NAVY YARD PLAZA
CITY: BOSTON
STATE: MA
ZIP: 02129
FORMER COMPANY:
FORMER CONFORMED NAME: EASYWEB INC
DATE OF NAME CHANGE: 20010213
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-09-29
0
0001107421
ZIOPHARM ONCOLOGY INC
ZIOP
0001846045
Vieser Jaime
C/O ZIOPHARM ONCOLOGY, INC.
ONE FIRST AVENUE, PARRIS BLDG 34
BOSTON
MA
02129
1
0
0
0
Common Stock
2021-09-29
4
P
0
100000
1.91
A
705321
D
Common Stock
100000
I
By UTMA for child
Common Stock
75000
I
By UTMA for child
Common Stock
75000
I
By UTMA for child
Common Stock
75000
I
By UTMA for child
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.90
to $1.96 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities
and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ Kevin Lafond, Attorney-in-Fact
2021-10-04